Evidence & regulatory context
- Mechanism
- Not recorded
- Target
- Not recorded
- Injury models
- TBI
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Preclinical/no trial
- ChEMBL max phase
- -1 / 4 (development scale, not regulatory approval)
- Synonyms
- Acocantherin; Gratus strophanthin; NSC-25485; Ouabain; Strophantin-g
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MouseTBIWeight-drop / impact-accelerationMaleIntraperitoneal1 microgram/kgChronic dosing regimen after closed head injury; acute single administration wa…
Model: Closed head injury (CHI) weight-drop model of traumatic brain injury
Chronic but not acute low-dose ouabain significantly improved recovery and functional outcome, reduced lesion size at 43 days and increased proliferating cells in the subventricular zone and around the injury site. Neuronal proliferation almost doubled versus vehicle while endothelial and astrocyte…
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.